ATP6V1C1

Across TCGA pan-cancer cohorts, ATP6V1C1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATP6V1C1 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ATP6V1C1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ATP6V1C1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where ATP6V1C1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.381	0.951	.006	12	view →
LSCC	DFS	Quartile	II,III,IV	0.861	0.512	.014	12	view →
LUAD	OS	Tertile	All	0.788	0.908	.035	4	view →
CCRCC	OS	Quartile	II,III,IV	1.000	0.214	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATP6V1C1–PDAC (OS)

Open the PDAC breakdown →